Janux Therapeutics Inc [JANX] stock prices are up 5.41% to $40.17 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The JANX shares have gain 13.83% over the last week, with a monthly amount drifted -13.39%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on May 30, 2024, when Scotiabank initiated its Sector Perform rating and assigned the stock a price target of $47. Previously, BTIG Research started tracking the stock with Buy rating on March 21, 2024, and set its price target to $62. On March 20, 2024, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $100 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $24 on April 06, 2023. William Blair initiated its recommendation with a Outperform.
The stock price of Janux Therapeutics Inc [JANX] has been fluctuating between $5.65 and $65.60 over the past year. Currently, Wall Street analysts expect the stock to reach $55.67 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $40.17 at the most recent close of the market. An investor can expect a potential return of 38.59% based on the average JANX price forecast.
Analyzing the JANX fundamentals
The Janux Therapeutics Inc [NASDAQ:JANX] reported sales of 15.13M for trailing twelve months, representing a surge of 741.72%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -4.36%, Pretax Profit Margin comes in at -2.91%, and Net Profit Margin reading is -2.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -0.09 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 37.95 points at the first support level, and at 35.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.58, and for the 2nd resistance point, it is at 42.99.
Ratios To Look Out For
It’s worth pointing out that Janux Therapeutics Inc [NASDAQ:JANX]’s Current Ratio is 57.34. On the other hand, the Quick Ratio is 57.34, and the Cash Ratio is 1.27. Considering the valuation of this stock, the price to sales ratio is 138.48, the price to book ratio is 3.19.
Transactions by insiders
Recent insider trading involved Lichter Jay, Director, that happened on Jun 03 ’24 when 1.5 million shares were sold. Acting Chief Financial Officer, Reardon Tighe completed a deal on Jun 03 ’24 to sell 0.82 million shares. Meanwhile, 10% Owner Avalon Ventures XI, L.P. sold 0.82 million shares on Jun 03 ’24.
